INTRODUCTION: Brodifacoum (BDF) is a superwarfarin that is used primarily as a rodenticide. There have been increasing numbers of reports of human cases of accidental or intentional BDF ingestion with high mortality rate. Its broad availability and high lethality suggest that BDF should be considered a potential chemical threat. Currently, there is no biomarker for early detection of BDF ingestion in humans; patients typically present with severe coagulopathy. Since we demonstrated earlier that warfarin can induce acute kidney injury with hematuria, we tested whether BDF would also lead to change in urinary biomarkers. MATERIAL AND METHODS: BDF was administered to Sprague Dawley rats via oral gavage. N-acetylcysteine (NAC) was given per os in drinking water 24 h prior to BDF. Urinalysis was performed at different times after BDF administration. Anticoagulation and serum creatinine levels were analyzed in the blood. RESULTS: We observed that within a few hours the animals developed BDF-dose-dependent transient hemoglobinuria, which ceased within 24 h. This was accompanied by a transient decrease in hematocrit, gross hemolysis and an increase in free hemoglobin in the serum. At later times, animals developed true hematuria with red blood cells in the urine, which was associated with BDF anticoagulation. NAC prevented early hemoglobinuria, but not late hematuria associated with BDF. CONCLUSIONS: We propose that transient early hemoglobinuria (associated with oxidative stress) with consecutive late hematuria (associated with anticoagulation) are novel biomarkers of BDF poisoning, and they can be used in clinical setting or in mass casualty with BDF to identify poisoned patients.
INTRODUCTION: Brodifacoum (BDF) is a superwarfarin that is used primarily as a rodenticide. There have been increasing numbers of reports of human cases of accidental or intentional BDF ingestion with high mortality rate. Its broad availability and high lethality suggest that BDF should be considered a potential chemical threat. Currently, there is no biomarker for early detection of BDF ingestion in humans; patients typically present with severe coagulopathy. Since we demonstrated earlier that warfarin can induce acute kidney injury with hematuria, we tested whether BDF would also lead to change in urinary biomarkers. MATERIAL AND METHODS:BDF was administered to Sprague Dawley rats via oral gavage. N-acetylcysteine (NAC) was given per os in drinking water 24 h prior to BDF. Urinalysis was performed at different times after BDF administration. Anticoagulation and serum creatinine levels were analyzed in the blood. RESULTS: We observed that within a few hours the animals developed BDF-dose-dependent transient hemoglobinuria, which ceased within 24 h. This was accompanied by a transient decrease in hematocrit, gross hemolysis and an increase in free hemoglobin in the serum. At later times, animals developed true hematuria with red blood cells in the urine, which was associated with BDF anticoagulation. NAC prevented early hemoglobinuria, but not late hematuria associated with BDF. CONCLUSIONS: We propose that transient early hemoglobinuria (associated with oxidative stress) with consecutive late hematuria (associated with anticoagulation) are novel biomarkers of BDF poisoning, and they can be used in clinical setting or in mass casualty with BDF to identify poisoned patients.
Authors: Kyle Ware; Polina Brodsky; Anjali A Satoskar; Tibor Nadasdy; Gyongyi Nadasdy; Haifeng Wu; Brad H Rovin; Udayan Bhatt; Jon Von Visger; Lee A Hebert; Sergey V Brodsky Journal: J Am Soc Nephrol Date: 2011-09-01 Impact factor: 10.121
Authors: A Ozcan; K Ware; E Calomeni; T Nadasdy; R Forbes; A A Satoskar; G Nadasdy; B H Rovin; L A Hebert; S V Brodsky Journal: Am J Nephrol Date: 2012-04-02 Impact factor: 3.754
Authors: E Maellaro; B Del Bello; A F Casini; M Comporti; D Ceccarelli; U Muscatello; A Masini Journal: Biochem Pharmacol Date: 1990-10-01 Impact factor: 5.858
Authors: Sergey V Brodsky; Anjali Satoskar; Jun Chen; Gyongyi Nadasdy; Jeremiah W Eagen; Mirza Hamirani; Lee Hebert; Edward Calomeni; Tibor Nadasdy Journal: Am J Kidney Dis Date: 2009-07-04 Impact factor: 8.860
Authors: Douglas L Feinstein; Belinda S Akpa; Manuela A Ayee; Anne I Boullerne; David Braun; Sergey V Brodsky; David Gidalevitz; Zane Hauck; Sergey Kalinin; Kathy Kowal; Ivan Kuzmenko; Kinga Lis; Natalia Marangoni; Michael W Martynowycz; Israel Rubinstein; Richard van Breemen; Kyle Ware; Guy Weinberg Journal: Ann N Y Acad Sci Date: 2016-05-31 Impact factor: 5.691
Authors: Douglas L Feinstein; Daniel G Nosal; Swetha Ramanathan; Jifang Zhou; Luying Chen; Ronald C Hershow; Richard B van Breemen; Erik Wright; John W Hafner; Israel Rubinstein Journal: Clin Toxicol (Phila) Date: 2019-11-18 Impact factor: 4.467
Authors: Matthew Lindeblad; Alexander Lyubimov; Richard van Breemen; Kamil Gierszal; Guy Weinberg; Israel Rubinstein; Douglas L Feinstein Journal: Toxicol Sci Date: 2018-10-01 Impact factor: 4.849
Authors: Kyle M Ware; Douglas L Feinstein; Israel Rubinstein; Prudhvi Battula; Jose Otero; Lee Hebert; Tzu-Fei Wang; Alexandra Ivanova; Shweta Chaudhary; Jessica Hemminger; Sergey V Brodsky Journal: Stroke Res Treat Date: 2017-07-20
Authors: Ajay K Medipally; Min Xiao; Brad H Rovin; Anjali A Satoskar; Iouri Ivanov; Shahzeb Qaisar; Sergey V Brodsky Journal: Physiol Rep Date: 2021-01